公开(公告)号：US20090111707A1

公开(公告)日：2009-04-30

申请号：US12067633

申请日：2006-09-21

申请人： John Foekens ,  John Martens ,  Serenella Eppenberger-Castori ,  Vincent Vuaroqueaux ,  Frederique Spyratos ,  Nadia Harbeck ,  Manfred Schmitt ,  Heinz Hoefler ,  Sabine Maier ,  Gunter Weiss ,  Ralf Lesche ,  Thomas Hildmann ,  Achim Plum

发明人： John Foekens ,  John Martens ,  Serenella Eppenberger-Castori ,  Vincent Vuaroqueaux ,  Frederique Spyratos ,  Nadia Harbeck ,  Manfred Schmitt ,  Heinz Hoefler ,  Sabine Maier ,  Gunter Weiss ,  Ralf Lesche ,  Thomas Hildmann ,  Achim Plum

IPC分类号： C40B30/04 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/16

摘要： The present invention relates to methods for predicting the outcome of anthracycline treatment of cell proliferative disorder patients. This is achieved by determining the expression level of at least one gene selected from the group consisting of PITX2; TFF1 and PLAU. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods.

摘要翻译： 本发明涉及预测细胞增殖性疾病患者蒽环类治疗结果的方法。 这通过确定选自PITX2的至少一种基因的表达水平来实现; TFF1和PLAU。 本发明还涉及可以在所述方法中使用的序列，寡核苷酸和抗体。

公开(公告)号：US10053735B2

公开(公告)日：2018-08-21

申请号：US12067633

申请日：2006-09-21

申请人： John Foekens ,  John W. Martens ,  Serenella Eppenberger-Castori ,  Vincent Vuaroqueaux ,  Frederique Spyratos ,  Nadia Harbeck ,  Manfred Schmitt ,  Heinz Hoefler ,  Sabine Maier ,  Gunter Weiss ,  Ralf Lesche ,  Thomas Hildmann ,  Achim Plum

发明人： John Foekens ,  John W. Martens ,  Serenella Eppenberger-Castori ,  Vincent Vuaroqueaux ,  Frederique Spyratos ,  Nadia Harbeck ,  Manfred Schmitt ,  Heinz Hoefler ,  Sabine Maier ,  Gunter Weiss ,  Ralf Lesche ,  Thomas Hildmann ,  Achim Plum

IPC分类号： C07H21/04 ,  C12Q1/68 ,  C12Q1/6886

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/16

摘要： The present invention relates to methods for predicting the outcome of anthracycline treatment of cell proliferative disorder patients. This is achieved by determining the expression level of at least one gene selected from the group consisting of PITX2; TFF1 and PLAU. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods.